Management of Inadequate Glycemic Control on Metformin

Introduction to Optimized Treatment

The American College of Physicians recommends adding either an SGLT-2 inhibitor or GLP-1 receptor agonist to the patient's current metformin regimen, while optimizing the metformin dose to 1000mg BID if tolerated, to reduce all-cause mortality, major adverse cardiovascular events, and progression of chronic kidney disease 1

Increase metformin to 1000mg BID if tolerated, as higher doses provide significantly greater HbA1c reduction without increasing gastrointestinal side effects is not a cited fact, however, titrate gradually by 500mg weekly to minimize gastrointestinal symptoms 2
Continue metformin even when adding other agents, as combination therapy is superior to monotherapy and metformin provides cardiovascular benefits 3, 4

SGLT-2 inhibitors should be added to reduce all-cause mortality, major adverse cardiovascular events, progression of chronic kidney disease, and hospitalization for congestive heart failure 1
GLP-1 agonists should be added to reduce all-cause mortality, major adverse cardiovascular events, and stroke risk 1

Prioritize SGLT-2 inhibitors if the patient has congestive heart failure, chronic kidney disease, or high cardiovascular risk without specific stroke concerns 1
Prioritize GLP-1 agonists if the patient has increased stroke risk, need for significant weight loss, or established atherosclerotic cardiovascular disease 1, 3, 4

Self-monitoring of blood glucose may be unnecessary when combining metformin with SGLT-2 inhibitors or GLP-1 agonists, as hypoglycemia risk is minimal 1
Target HbA1c of 7-8% for most adults with type 2 diabetes 1
If adding SGLT-2 or GLP-1 achieves adequate control, reduce or discontinue any existing sulfonylureas or long-acting insulins due to severe hypoglycemia risk 1
Monitor vitamin B12 levels with long-term metformin use, especially if neuropathy develops 2

Do not add a DPP-4 inhibitor, as the American College of Physicians explicitly recommends against this combination due to lack of mortality and morbidity benefit despite adequate glycemic control 1
Do not delay treatment intensification - reassess every 3-6 months and adjust promptly if targets are not met 3, 5
Do not use sulfonylureas or insulin as second-line agents unless SGLT-2 inhibitors and GLP-1 agonists are contraindicated, unavailable, or unaffordable, as these older agents are inferior for reducing mortality and morbidity 1